TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS

被引：0

作者：

Harrison, Stephen A. ^{[1
]}

Abdelmalek, Manal F. ^{[2
]}

Neff, Guy W. ^{[3
]}

Gunn, Nadege ^{[1
]}

Guy, Cynthia D. ^{[2
]}

Alkhouri, Naim ^{[4
]}

Bashir, Mustafa ^{[2
]}

Freilich, Bradley ^{[5
]}

Almeda, Jose ^{[6
]}

Knapple, Whitfield ^{[7
]}

Kohli, Anita ^{[4
]}

Khazanchi, Arun ^{[8
]}

Sheikh, Muhammad Y. ^{[9
]}

Leibowitz, Mark ^{[10
]}

Hogan, Reed ^{[11
]}

White, Judith ^{[12
]}

Kayali, Zeid ^{[13
]}

Rinella, Mary E. ^{[14
]}

Siddiqui, Mohammad S. ^{[15
]}

Kipnes, Mark ^{[16
]}

Moussa, Sam E. ^{[17
]}

Ortiz-Lasanta, Grisell ^{[18
]}

Poulos, John ^{[19
]}

Younes, Ziad ^{[20
]}

Bansal, Meena B. ^{[21
]}

Baum, Seth J. ^{[22
]}

Borg, Brian ^{[23
]}

Ruane, Peter J. ^{[24
]}

White, Alexander ^{[25
]}

Merkes, Kevin ^{[26
]}

Rashmee, Patil ^{[27
]}

Thuluvath, Paul J. ^{[28
,29
]}

Gottwald, Mildred ^{[30
]}

Khan, Mujib ^{[30
]}

Chen, Charles ^{[30
]}

Yan, Andrew Z. ^{[30
]}

Melchor-Khan, Liza ^{[30
]}

Chang, William ^{[30
]}

DePaoli, Alex ^{[30
]}

Ling, Lei ^{[30
]}

Lieu, Hsiao ^{[30
]}

机构：

[1] Pinnacle Clin Res, San Antonio, TX USA

[2] Duke Univ, Durham, NC USA

[3] Covenant Res & Clin, LLC, Sarasota, FL USA

[4] Arizona Liver Hlth, Chandler, AZ USA

[5] Kansas City Res Inst, Kansas City, MO USA

[6] Doctors Hosp Renaissance, Edinburg, TX USA

[7] Arkansas Gastroenterol, Hot Springs, AR USA

[8] Florida Res Inst, Bradenton, FL USA

[9] Fresno Clin Res Ctr, Fresno, CA USA

[10] Natl Res Inst, Delhi, NY USA

[11] GI Assoc & Endoscopy Ctr, Wausau, WI USA

[12] Bioclin Res, Princeton, NJ USA

[13] Inland Empire Liver Fdn, Rialto, CA USA

[14] Northwestern Univ, Evanston, IL USA

[15] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA

[16] Diabet & Glandular Dis Clin, San Antonio, TX USA

[17] Adobe Clin Res, Tucson, AZ USA

[18] Fdn Invest, San Juan, PR USA

[19] Cumberland Res Assoc, Cumberland, MD USA

[20] Gastro One, Germantown, TN USA

[21] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA

[22] Excel Med Clin Trials, Boca Raton, FL USA

[23] Southern Therapy & Adv Res, Madison, NJ USA

[24] Ruane Clinical Res Grp Inc, Los Angeles, CA USA

[25] Progress Med Res, Port Orange, FL USA

[26] Alliance Clin Res, Alliance, OH USA

[27] South Texas Res Inst, Edinburg, TX USA

[28] Mercy Med Ctr, Baltimore, MD USA

[29] Univ Maryland, Sch Med, Baltimore, MD USA

[30] Ngm Biopharmaceut, San Francisco, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：5A / 6A

页数：2

共 50 条

[31] A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease
Howard, Joanna
Kuo, Kevin H. M.
Oluyadi, Abdulafeez
Shao, Hui
Morris, Susan
Zaidi, Ahmar U.
Van Beers, Eduard J.
Thien, Swee Lay
BLOOD, 2021, 138
[32] A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor: ELATE Trial
Patterson, K.
Alibhai, N.
Khosla, D.
James, L.
MOVEMENT DISORDERS, 2024, 39 : S721 - S721
[33] EFFICACY AND SAFETY OF NIPOCALIMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: TOPLINE RESULTS FROM THE DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 3 VIVACITY-MG3 STUDY
Vu, Tuan
Antozzi, Carlo
Ramchandren, Sindhu
Nowak, Richard
Farmakidis, Constantine
Bril, Vera
De Bleecker, Jan
Yang, Huan
Minks, Eduard
Park, Jin-Sung
Grudniak, Mariusz
Smilowski, Marek
Sevilla, Teresa
Hoffmann, Sarah
Sivakumar, Kumaraswamy
Youssef, Eriene
Sanga, Panna
Karcher, Keith
Zhu, Yaowei
Ling, Leona
Sun, Hong
MUSCLE & NERVE, 2024, 70 (03) : 613 - 614
[34] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY OF INEBILIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MINT): TOPLINE EFFICACY AND SAFETY FINDINGS
Nowak, Richard
Utsugisawa, Kimiaki
Benatar, Michael
Ciafaloni, Emma
Leite, M. Isabel
Vissing, John
Tang, Fengming
Wu, Yanping
Rojavin, Mikhail
Rampal, Nishi
Howard, James, Jr.
MUSCLE & NERVE, 2024, 70 (03) : 653 - 654
[35] HL301 in the treatment of acute bronchitis: a phase 2b, randomized, double-blind, placebo-controlled, multicenter study
Yoon, Sang Won
Park, Myung Jae
Rhee, Chin Kook
Park, Joo Hun
Lee, Sang Yeub
Kim, Do Jin
Kim, Dong Gyu
Kim, Jae Yeol
KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (01): : 133 - 141
[36] A phase 2b randomized, double-blind, placebo-controlled trial of ubrogepant for acute treatment of a migraine attack
Lipton, R. B.
Voss, T.
Dodick, D. W.
Dupre, N.
Ge, J.
Bachman, R.
Assaid, C.
Aurora, S. K.
Michelson, D.
HEADACHE, 2016, 56 : 7 - 7
[37] A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
Lafayette, Richard
Barbour, Sean
Israni, Rubeen
Wei, Xuelian
Eren, Necmi
Floege, Juergen
Jha, Vivekanand
Kim, Sung Gyun
Maes, Bart
Phoon, Richard K. S.
Singh, Harmeet
Tesar, Vladimir
Lin, Celia J. F.
Barratt, Jonathan
KIDNEY INTERNATIONAL, 2024, 105 (06) : 1306 - 1315
[38] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
Ayer, David W.
Skljarevski, Vladimir
Ford, Janet H.
Nyhuis, Allen W.
Lipton, Richard B.
Aurora, Sheena K.
HEADACHE, 2018, 58 (08): : 1225 - 1235
[39] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 27 - 28
[40] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 19

← 1 2 3 4 5 →